Navigation Links
Valensa to Market Neptune Krill Oil NKO(R) Formulations for Joint Health and Eye Health Dietary Supplements

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Valensa International (Eustis, FL USA) announced today that it has reached agreement with Neptune Technologies & Bioressources Inc. (Laval, Quebec, CANADA) for an exclusive, worldwide license to incorporate and market Neptune Krill Oil NKO® in condition-specific dietary supplement formulas targeting eye health and joint health. Valensa plans on using the unique biofunctional properties of the highly bioavailable Omega-3 phospholipids in NKO® in conjunction with several of its proprietary ingredients such as Zanthin® Natural Astaxanthin, extending its current platform of patented eye health formulations. Valensa has also developed and applied for IP protection for a new and revolutionary range of joint and eye health formulations featuring NKO® and other ingredients. Valensa is in discussions with customers and plans to launch the new patent-pending eye and joint health formulations during the first quarter of 2010. The company is currently conducting clinical trials to demonstrate the effectiveness of these new formulations. The wholesale US markets for eye health and joint health formulations are estimated at $60 million and $712 million respectively.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, NKO® is an ideal ingredient for the development of new supplement formulations for the company's signature eye health portfolio as well as the joint health market. "In the area of Omega-3s, NKO® is by far the most effective product from a bioavailability standpoint and NKO® is manufactured to quality standards that are in line with Valensa's previously stated commitment to the market. Based on the completed clinical trials on NKO® to date, and the new trials we are currently conducting, we are excited about the opportunity to work with Neptune Technologies to market and promote truly innovative eye health and joint health formulations," he said. Moerck went on to point out that the addition of NKO® to the company's product portfolio extends the range of specialty Omega-3 products, which includes its Tresalbio(TM), Chia Gold and ChiaMax chia-based offerings, to the nutraceutical and functional foods markets.

NKO®: A Better Omega-3

Among the many forms of Omega-3 on the market today, marine oils enjoy a special position because of their levels of eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) and the number of clinical trials proving efficacy. NKO®, like fish oil, contains EPA and DHA - but in a superior, more bioavailable form. In fish oil, omega-3 fatty acids are found as triglycerides whereas in NKO® these nutrients are primarily present as EPA and DHA bound phospholipids - enabling far greater bioavailability. Studies show that human cells will readily absorb 95-98% of NKO® phospholipids versus only 65% absorption of fish oil fatty acids. This makes NKO® significantly more potent, offering possible additional therapeutic effects at lower dosages. NKO® also has a significant advantage over fish oil in ORAC-based antioxidant potential. NKO® is a source of astaxanthin, an ultra-potent antioxidant that protects cells and membranes from oxidative damage and, in combination with phospholipids, is a natural anti-inflammatory agent. From a consumer acceptance standpoint, NKO® is much more easily tolerated - virtually eliminating "burp back," which is common with fish oil.

According to Moerck, the upside potential for NKO®-based formulations from Valensa is substantial. "In incorporating NKO® into proprietary eye health and joint health formulations, we are addressing a range of market needs - from enhanced efficacy and performance to consumer preference for pleasant-tasting, small-dosage forms that are easy to use on a regular basis. This is a remarkable opportunity and we look forward to coming to market with exciting new products," he said. For more information, visit

    For further information, contact:

    Dr. Rudi E. Moerck, President
    Voice: 210-632-0695
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit

SOURCE Valensa International

SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astaxanthin Stability Breakthrough Achieved by Valensa
2. Valensa Selects Parry Organic Spirulina as Ingredient of Choice for Premium Product Development
3. Valensa Completes Second Expansion of Astaxanthin Capacity
4. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
5. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
6. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
7. Michigan Society for Healthcare Planning and Marketing to Hold Fall Conference
8. bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
9. Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
10. Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services
11. Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: